Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : PhOx430
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Taiho Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Taiho will obtain option rights for PhOx430, a first-in-class small molecule targeting GnT-V and additional undisclosed compounds and to exclusively develop and commercialize the compounds in Japan and certain other territories in As...
Brand Name : PhOx430
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 25, 2023
Lead Product(s) : PhOx430
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Taiho Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?